Healthcare - Biotechnology - NASDAQ - GB
$ 0.682
-38.6 %
$ 3.53 M
Market Cap
-1.1
P/E
CASH FLOW STATEMENT
-7.72 M
OPERATING CASH FLOW
625 K
INVESTING CASH FLOW
4.09 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aptorum Group Limited
| Net Income | -4.34 M |
| Depreciation & Amortization | 1.13 M |
| Capital Expenditures | -3.01 K |
| Stock-Based Compensation | 1.27 M |
| Change in Working Capital | 407 K |
| Others | -6.6 M |
| Free Cash Flow | -7.73 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (4.3) | (11.5) | (27.1) | 4.9 | (20.1) | (15.1) | (2.5) |
| Depreciation & Amortization | 1.1 | 1.2 | 1.2 | 1.3 | 1.3 | 0.7 | 58.9 K |
| Deferred Income Tax | 0 | 0 | 8.0 | (24.5) | (1.5) | 0 | 0 |
| Stock Based Compensation | 1.3 | 1.6 | 1.7 | 1.5 | 1.6 | 0 | 0 |
| Other Operating Activities | (6.2) | (5.0) | 0.6 | 0.8 | 4.1 | 4.8 | (2.9) |
| Change in Working Capital | 0.4 | 1.4 | 1.0 | 45.6 K | 1.2 | (0.4) | (0.2) |
| Cash From Operations | (7.7) | (12.3) | (14.7) | (15.9) | (13.4) | (10.0) | (5.8) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 3.01 K | (0.2) | (0.1) | (0.2) | (1.1) | (6.1) | (3.1) |
| Other Items | 0.6 | 2.6 | 16.6 | 2.0 | 1.0 | 2.31 K | 15.9 |
| Cash From Investing Activities | 0.6 | 2.4 | 16.5 | 1.8 | (0.1) | (6.1) | 12.8 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 2.6 | 6.5 | (2.0) | (4.4) | (7.3) | 16.1 | 0.5 |
| Dividends Paid | 0 | 0 | 0 | (0.8) | 0 | 0 | 0 |
| Other Financing Activities | 38 K | 0.2 | 0.8 | (0.7) | 0 | (1.6) | 0 |
| Cash From Financing Activities | 4.1 | 6.6 | 2.8 | 12.4 | (7.3) | 25.5 | 9.1 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (3.0) | (3.2) | 4.6 | (1.7) | (20.8) | 9.4 | 16.1 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (7.7) | (12.5) | (14.8) | (16.1) | (14.5) | (16.1) | (8.8) |